Another quarter of double-digit growth; full-year targets exceeded
25/02/21 -"Benefitting from sustained demand for COVID-19 testing solutions, bioMerieux reported another quarter of double-digit growth in Q4 20. Interestingly, the FY20 targets were exceeded, both on the sales ..."
Pages
71
Language
English
Published on
25/02/21
You may also be interested by these reports :
28/09/26
Along with the downgrades to our DCF and NAV, we now apply a 10% discount to our peer-based valuation metrics. This reflects S&N’s growth lagging ...
14/09/26
Equity markets ended lower on the week ending September 11 as the renewed surge in energy prices revived inflation concerns and pushed bond yields ...
11/09/26
MedTech sector momentum has finally turned constructive in recent weeks, a welcome change after a multi-year stretch of post-covid destocking, supply ...
07/09/26
We have revised our estimates upwards and removed the 20% discount previously applied to the peer-based valuation. This optimism is supported by ...